Cargando…

Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry

INTRODUCTION: Inflammatory bowel disease (IBD) frequently requires chronic immunosuppressive treatment and active involvement from patients during treatment decision making. Information about the risk of developing adverse drug reactions (ADRs) to IBD therapies is required in this process. OBJECTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giraud, Eline L., Thomas, Pepijn W. A., van Lint, Jette A., van Puijenbroek, Eugene P., Römkens, Tessa E. H., West, Rachel L., Russel, Maurice G. V. M., Jansen, Jeroen M., Jessurun, Naomi T., Hoentjen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053178/ https://www.ncbi.nlm.nih.gov/pubmed/33538994 http://dx.doi.org/10.1007/s40264-021-01045-3

Ejemplares similares

Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
por: Thomas, Pepijn W. A., et al.
Publicado: (2021)

Inflammatory bowel disease patients provide reliable self‐reported medical information: A multicentre prospective pharmacovigilance monitoring system
por: Thomas, Pepijn W. A., et al.
Publicado: (2020)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study
por: Thomas, Pepijn W A, et al.
Publicado: (2022)

Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study
por: Thomas, Pepijn W.A., et al.
Publicado: (2022)

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor
por: van Lint, Jette A., et al.
Publicado: (2023)

Development of a Framework Structuring Themes in the Course of Adverse Drug Reactions from a Patient’s Perspective
por: van Lint, Jette A., et al.
Publicado: (2023)

Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers
por: Jessurun, Naomi T., et al.
Publicado: (2020)

Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
por: Derikx, Lauranne A A P, et al.
Publicado: (2020)

Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study
por: Simsek, Melek, et al.
Publicado: (2023)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Role of Drug–Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity
por: Jessurun, Naomi T., et al.
Publicado: (2021)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
por: De Jong, Michiel E, et al.
Publicado: (2019)

Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy
por: Jansen, Fenna M., et al.
Publicado: (2023)

Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease: Ubiquitous Yet Suboptimally Managed
por: Loveikyte, Roberta, et al.
Publicado: (2022)

Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn’s Disease Patients: A Case Report and Review of the Literature
por: Thomas, Pepijn W A, et al.
Publicado: (2020)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Lower gastrointestinal bleeding in a patient receiving sevelamer: Case report
por: Schoot, Tessa S, et al.
Publicado: (2021)

Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes
por: Jansen, Fenna M, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
por: Sivridaş, Merve, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
por: Jansen, Fenna M, et al.
Publicado: (2023)

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
por: Biemans, Vince B C, et al.
Publicado: (2020)

Intensive monitoring of duloxetine: results of a web-based intensive monitoring study
por: Härmark, Linda, et al.
Publicado: (2012)

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease
por: Crouwel, Femke, et al.
Publicado: (2022)

A207 CLONAL PATTERNS BETWEEN POUCH NEOPLASIA AND PRIOR COLORECTAL NEOPLASIA IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN EXPLORATORY COHORT STUDY
por: Van Lierop, L, et al.
Publicado: (2023)

Post-Menopausal Vaginal Hemorrhage Related to the Use of a Hop-Containing Phytotherapeutic Product
por: van Hunsel, Florence, et al.
Publicado: (2015)

The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
por: Rolfes, Leàn, et al.
Publicado: (2016)

No Increased Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease and Postinflammatory Polyps
por: de Jong, Michiel E, et al.
Publicado: (2020)

Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy
por: Fens, Tanja, et al.
Publicado: (2021)

Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn’s Disease
por: Savelkoul, E H J, et al.
Publicado: (2022)

A comparative analysis of tioguanine versus low‐dose thiopurines combined with allopurinol in inflammatory bowel disease patients
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Increased Colorectal Neoplasia Risk in Patients with Inflammatory Bowel Disease and Serrated Polyps with Dysplasia
por: de Jong, Michiel E., et al.
Publicado: (2022)

Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes
por: Voskuil, M D, et al.
Publicado: (2020)

Patients Prioritize a Low-volume Bowel Preparation in Colitis-associated Colorectal Cancer Surveillance: A Discrete Choice Experiment
por: Wijnands, Anouk M, et al.
Publicado: (2021)

How can patient registries facilitate guideline-based healthcare? A retrospective analysis of the CEDATA-GPGE registry for pediatric inflammatory bowel disease
por: Leiz, M., et al.
Publicado: (2023)

Patient preferences and expectation for feedback on adverse drug reaction reports submitted in Ghana
por: Sabblah, George Tsey, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vlkfbohgo0jhb04fqcb97uo7at